Graves´ disease

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
4 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
H Endocrinology (ATC H) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
BTK inhibitor 1 substance
Unknown / small molecule 1 substance
Azole antifungal 1 substance
Phase III: 1 Phase II: 1 Phase I: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Azienda Ospedaliero Universitaria Pisana Academic
    SODIUM IODIDE (131I); THIAMAZOLE
    2024-518452-23-00 1 country n=52
    Pending

Phase II

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    RILZABRUTINIB
    2025-521023-75-00 3 countries 2025 n=30
    Recruiting

Phase I

2 trials
  • Lycia Therapeutics Inc. Commercial
    IMP not specified
    2025-524053-14-00 1 country 2026 n=48
    Recruiting
  • Merida Biosciences Inc. Commercial
    IMP not specified
    2025-523823-23-00 1 country n=28
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Lycia Therapeutics Inc. Commercial 1 Phase I 1
Merida Biosciences Inc. Commercial 1 Phase I 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 1
Azienda Ospedaliero Universitaria Pisana Academic 1 Phase III 0
New trials by year
2025
1
2026
1
← All indication landscapes